Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + DP chemotherapy + tislelizumab for stage IIIB-IV lung squamous cell carcinoma
ChiCTR2000032825Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar, tislelizumab, docetaxel and cisplatin in Pulmonary squamous cell carcinoma, sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Started May 2020; status: recruiting.
02
Drugs
endostartislelizumabdocetaxelcisplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2000032825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032825.